Llamas‐Velasco M, et al. - Given that off‐label treatment with reduced doses of biological therapies for moderate‐severe psoriasis is used, however, its effectiveness, safety, and persistence are unknown, researchers sought to compare reduced doses with standard an escalated doses and study predictive factors for a successful reduction of doses lasting more than 6 months. Three hundred three subcutaneous treatments (33% with reduced doses and 29% with escalated doses) were included. The findings indicate that dose reduction should be done early when a good response is obtained (PASI 90 or PASI < 3 in two consecutive visits) as this dose appears safe and does not present any problems with persistence or adverse effects.